Zentalis Pharmaceuticals, Inc. (ZNTL)
3.99
-0.12
(-2.92%)
USD |
NASDAQ |
Sep 04, 16:00
3.995
0.00 (0.00%)
After-Hours: 20:00
Price Chart
Key Stats
| Price and Performance | |
|---|---|
| Market Cap | 285.96M |
| 52 Week High (Daily) | |
| 52 Week Low (Daily) | |
| All-Time High (Daily) | |
| Year to Date Total Returns (Daily) | |
| 1 Month Total Returns (Daily) | |
| 1 Year Total Returns (Daily) | 125.4% |
| Valuation | |
| PE Ratio | -- |
| PE Ratio (Forward) | |
| PS Ratio | -- |
| Price to Book Value | 1.991 |
| EV to EBITDA | |
| Dividend | |
|---|---|
| Dividend | -- |
| Dividend Yield (Forward) | |
| Financials | |
| Revenue (5 Year Growth) | |
| Revenue (Quarterly YoY Growth) | |
| EPS Diluted (5 Year Growth) | |
| EPS Diluted (Quarterly YoY Growth) | |
| Debt to Equity Ratio | 0.2624 |
| Return on Equity | |
| Return on Assets | |
| Risk | |
| Beta (5Y) | |
| Max Drawdown (5Y) | 98.77% |
Profile
| Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into clinical practice, aiming to equip physicians with a targeted, orally available medicine that enhances treatment experience, choice, and outcomes. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA. |
| URL | http://www.zentalis.com |
| Investor Relations URL | https://ir.zentalis.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 10, 2026 (est.) |
| Last Earnings Release | Aug. 06, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |
Profile
| Zentalis Pharmaceuticals, Inc. is a clinical oncology innovator developing an oral, non-chemotherapy, biomarker-driven treatment approach for ovarian cancer and multiple tumor types. The therapeutics development and biomarker expertise is advancing monotherapy and combination studies of its investigational potential first-in-class WEE1 inhibitor, azenosertib. It is focused on translating WEE1 science into clinical practice, aiming to equip physicians with a targeted, orally available medicine that enhances treatment experience, choice, and outcomes. The company was founded by Kevin D. Bunker and Cam Gallagher on December 23, 2014 and is headquartered in San Diego, CA. |
| URL | http://www.zentalis.com |
| Investor Relations URL | https://ir.zentalis.com/ |
| HQ State/Province | California |
| Sector | Health Care |
| Industry | Biotechnology |
| Equity Style | Small Cap Value |
| Next Earnings Release | Nov. 10, 2026 (est.) |
| Last Earnings Release | Aug. 06, 2026 |
| Next Ex-Dividend Date | N/A |
| Last Ex-Dividend Date | N/A |